BiotechTube

GTX-104 + Nimodipine Capsules

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aneurysmal Subarachnoid Hemorrhage

Conditions

Aneurysmal Subarachnoid Hemorrhage

Trial Timeline

Aug 26, 2021 → Feb 24, 2022

NCT ID
NCT05418348

About GTX-104 + Nimodipine Capsules

GTX-104 + Nimodipine Capsules is a phase 1 stage product being developed by Grace Therapeutics for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT05418348. Target conditions include Aneurysmal Subarachnoid Hemorrhage.

What happened to similar drugs?

0 of 4 similar drugs in Aneurysmal Subarachnoid Hemorrhage were approved

Approved (0) Terminated (1) Active (3)
🔄Clazosentan + PlaceboIdorsiaPhase 3
❌Clazosentan 5 m/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 3
🔄Clazosentan + PlaceboIdorsiaPhase 3
🔄GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05418348Phase 1Completed

Competing Products

8 competing products in Aneurysmal Subarachnoid Hemorrhage

See all competitors
ProductCompanyStageHype Score
erythropoietin betaRochePhase 2
35
DenosumabAmgenPhase 2
31
Clazosentan + PlaceboIdorsiaPhase 3
34
ClazosentanIdorsiaPhase 2
29
Clazosentan 5 m/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 3
26
Clazosentan + PlaceboIdorsiaPhase 3
34
Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 2
29
GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3
34